Acetaminophen
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1968
- First approval year
- 1968
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Acetaminophen
- Molecular weight
- 151.16
- Structure (SMILES)
- CC(=O)Nc1ccc(O)cc1
- abdine
- Abdine
- acephen
- Acephen
- acetaminophen
- Acetaminophen
- acetaminophen component of allay
- Acetaminophen component of allay
- acetaminophen component of anexsia
- Acetaminophen component of anexsia
- acetaminophen component of anoquan
- Acetaminophen component of anoquan
- acetaminophen component of apadaz
- Acetaminophen component of apadaz
- acetaminophen component of bancap
- Acetaminophen component of bancap
- acetaminophen component of bancap hc
- Acetaminophen component of bancap hc
- acetaminophen component of bucet
- Acetaminophen component of bucet
- acetaminophen component of butapap
- Acetaminophen component of butapap
- acetaminophen component of co gesic
- Acetaminophen component of co-gesic
- acetaminophen component of codrix
And 173 more, listed on the interactive page.
- 10 mg hc 325 mg apap
- 1000 mg acetaminophen
- 1000 mg Acetaminophen
- 750 mg paracetamol
- acetaminophen
- Acetaminophen
- Acetaminophen (Newaminophen Premix)
- Acetaminophen (Ofirmev)
- Acetaminophen (or equivalent)
- Acetaminophen (or similar antipyretic)
- Acetaminophen (paracetamol) or equivalent
- Acetaminophen (Standard of Care)
- Acetaminophen (Tylenol extra strength)
- Acetaminophen (Tylenol Extra Strength)
- Acetaminophen [HSDB]
- Acetaminophen [JAN]
- Acetaminophen [MI]
- Acetaminophen [ORANGE BOOK]
- Acetaminophen [USP IMPURITY]
- Acetaminophen [USP MONOGRAPH]
- Acetaminophen [USP-RS]
- Acetaminophen [VANDF]
- Acetaminophen 1 G Oral Tablet
- Acetaminophen 1000 mg
- Acetaminophen 1000mg
And 229 more, listed on the interactive page.
- CAS registry numbers
- 103-90-2
- ChEMBL ID
- CHEMBL112
- InChIKey
- RZVAJINKPMORJF-UHFFFAOYSA-N
- PubChem compound IDs
- 1983
- RxNorm IDs (RxCUI)
- 161
- FDA ingredient codes (UNII)
- 362O9ITL9D
- N02BE01
- N02BE51
- N02BE71
Sources for recorded values
- Applicant
- TARO
- Approval date
- 22 Apr 1980
- Application number
- NDA018337
- Patents
- 88
- Designations
- 0
- Earliest recorded loss of exclusivity
- 21 Dec 2041
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Boxed warning
- Yes
- Pharmacology name
- paracetamol
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
- Action type
- Inhibitor
- Target
- COX-1
- Gene symbol
- COX-1
- Action type
- Inhibitor
- Target
- COX-2
- Gene symbol
- COX-2
- Action type
- Inhibitor
- Target
- TRPV4
- Gene symbol
- TRPV4
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- COX-1
- Gene symbol
- PTGS1
- Protein identifier
- P23219
- Median affinity
- 3.94
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- COX-2
- Gene symbol
- PTGS2
- Protein identifier
- P35354
- Median affinity
- 4.59
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- TRPV4
- Gene symbol
- TRPV4
- Protein identifier
- Q9HBA0
- Median affinity
- 6.52
- Affinity units
- pIC50
- Mechanism
- Anandamide amidohydrolase inhibitor
- Action type
- Inhibitor
- Target
- Fatty-acid amide hydrolase 1
- Protein identifier
- O00519
- Mechanism
- Cyclooxygenase inhibitor
- Action type
- Inhibitor
- Target
- Cyclooxygenase
- Protein identifier
- P23219
- Mechanism
- Cyclooxygenase inhibitor
- Action type
- Inhibitor
- Target
- Cyclooxygenase
- Protein identifier
- P35354
- Mechanism
- Vanilloid receptor opener
- Action type
- OPENER
- Target
- Transient receptor potential cation channel subfamily V member 1
- Protein identifier
- Q8NER1
- Mechanism
- Anandamide amidohydrolase inhibitor
- Action type
- Inhibitor
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
- Action type
- Inhibitor
- Target
- Cyclooxygenase
- Mechanism
- Vanilloid receptor opener
- Action type
- OPENER
- Target
- Transient receptor potential cation channel subfamily V member 1
- Action type
- Agonist
- Gene symbol
- CNR1
- Protein identifier
- P21554
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Inhibitor
- Gene symbol
- PTGS2
- Protein identifier
- P35354
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- OPENER
- Gene symbol
- TRPV1
- Protein identifier
- Q8NER1
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Leukemia, Lymphocytic, Chronic, B-Cell
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000095
- Subject identifier
- D015451
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000220
- Subject identifier
- D054198
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000294
- Subject identifier
- D001749
- Condition
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000339
- Subject identifier
- D015464
- Condition
- Crohn Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Melanoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Hypertension
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Immune System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000540
- Subject identifier
- D007154
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Wounds and Injuries
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000546
- Subject identifier
- D014947
- Condition
- Leukemia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Nervous System Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000618
- Subject identifier
- D009422
- Condition
- Pre-Eclampsia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000668
- Subject identifier
- D011225
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Malaria
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001068
- Subject identifier
- D008288
- Condition
- Obesity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
And 95 more, listed on the interactive page.
- Condition identifier
- EFO_0000339
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0000540
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000546
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000551
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000618
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000668
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001068
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001074
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001378
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002460
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003865
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003890
- Condition identifier
- EFO_0003925
- Condition identifier
- EFO_0003926
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003956
- Condition identifier
- EFO_0004209
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004253
- Highest recorded phase
- 3
And 177 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Warning
- Black Box Warning
- Effect
- misuse
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Warning
- Black Box Warning
- Effect
- hepatotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- misuse
- Country
- United States
- Warning
- Black Box Warning
- Effect
- nephrotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- vascular toxicity
- Country
- United States
- Event
- acute hepatic failure
- Reports
- 1,454
- Reporting signal score
- 3,939.34
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 675
- Reporting signal score
- 2,004.72
- Event
- arthropathy
- Reports
- 756
- Reporting signal score
- 671.512
- Event
- blister
- Reports
- 787
- Reporting signal score
- 814.029
- Event
- cholestasis
- Reports
- 879
- Reporting signal score
- 1,306.98
- Event
- coma
- Reports
- 1,191
- Reporting signal score
- 1,527.81
- Event
- confusional state
- Reports
- 1,295
- Reporting signal score
- 614.181
- Event
- discomfort
- Reports
- 747
- Reporting signal score
- 902.733
- Event
- drug abuse
- Reports
- 983
- Reporting signal score
- 883.149
- Event
- drug hypersensitivity
- Reports
- 2,750
- Reporting signal score
- 1,687.54
- Event
- drug intolerance
- Reports
- 1,041
- Reporting signal score
- 558.928
- Event
- drug-induced liver injury
- Reports
- 739
- Reporting signal score
- 849.827
- Event
- duodenal ulcer perforation
- Reports
- 449
- Reporting signal score
- 1,240.84
- Event
- folliculitis
- Reports
- 605
- Reporting signal score
- 1,474.86
- Event
- gastrointestinal disorder
- Reports
- 802
- Reporting signal score
- 636.492
- Event
- glossodynia
- Reports
- 686
- Reporting signal score
- 1,283.35
- Event
- hand deformity
- Reports
- 702
- Reporting signal score
- 1,604.57
- Event
- helicobacter infection
- Reports
- 466
- Reporting signal score
- 1,064.49
- Event
- hepatic enzyme increased
- Reports
- 1,380
- Reporting signal score
- 1,578.1
- Event
- hepatic failure
- Reports
- 618
- Reporting signal score
- 919.302
- Event
- hepatitis
- Reports
- 769
- Reporting signal score
- 936.937
- Event
- hepatitis acute
- Reports
- 351
- Reporting signal score
- 596.551
- Event
- hepatocellular injury
- Reports
- 1,513
- Reporting signal score
- 2,925.79
- Event
- hepatotoxicity
- Reports
- 694
- Reporting signal score
- 950.279
- Event
- hypersensitivity
- Reports
- 1,578
- Reporting signal score
- 941.066
And 28 more, listed on the interactive page.
- NCT00000425
- NCT00240786
- NCT00240799
- NCT00298974
- NCT00371696
- NCT01420666
- NCT02845271
- NCT00003346
- NCT00029770
- NCT00078559
- NCT04629248
- NCT00092313
- NCT00092326
- NCT00152854
- NCT00236483
- NCT00236535
- NCT00240825
- NCT00240838
- NCT00240851
- NCT00240864
- NCT00261586
- NCT00292214
- NCT00299039
- NCT00344045
- NCT00378547
And 418 more, listed on the interactive page.
- Dose
- 2 tablets
- How often
- Every 6 hours
- Do not take for more than 10 days unless directed by a doctor
- Do not take more than 6 tablets in 24 hours
- Hydrogen bond acceptors
- 2
- Hydrogen bond donors
- 2
- Polar surface area
- 49.33
- Calculated partition coefficient (ALogP)
- 1.35
- Calculated partition coefficient (XLogP)
- 0.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 11
- Molecular formula
- C8H9NO2
- Monoisotopic mass
- 151.063328530
- Natural product
- No
- 0054-0650
- 0054-0843
- 0054-3000
- 0121-0504
- 0121-1008
- 0121-1544
- 0121-2316
- 0121-4772
- 0143-9150
- 0143-9386
- 0143-9432
- 0245-0410
- 0245-0411
- 0245-0412
- 0264-4050
- 0264-4100
- 0406-0123
- 0406-0124
- 0406-0125
- 0406-0376
- 0406-0377
- 0406-0378
- 0406-0483
- 0406-0484
- 0406-0485
And 542 more, listed on the interactive page.
- Recorded assays
- 6,156
- Active assays
- 48
- Confirmatory
- Other
- Screening
- Summary
- Analgesics, Non-Narcotic
- Antipyretics
These details could not be displayed.
Related records
Trials (1,955)
- "A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation"
- "Postoperative Pain Following Laser-Assisted Root Canal Treatment: A Randomized Clinical Trial"
- 4-methylpyrazole and Acetaminophen Metabolism
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting
- A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis
- A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
- A 5-treatment, Study in Healthy Volunteers to Assess The Safety, Tolerability, and Pharmacokinetics of Four Controlled Release (CR) Pregabalin Tablet Formulations and the Immediate Release (IR) Formulation Administered Fasted
- A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804
- A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms
- A Bioequivalence Study of a New Paracetamol Oral Suspension 24mg/ml Compared to the Marketed Paracetamol Oral Suspension (Panadol Baby and Infant 24mg/ml) in Healthy Adult Subjects
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
- A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses
- A Clinical Study Intended To Compare Treatment With Voriconazole To Treatment With Amphotericin Followed By Fluconazole In Patients With Candidemia, A Serious Fungus Infection Of The Blood.
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Approved for (6)
- Arthritic joint disease
- Common cold
- Dysmenorrhea
- Influenza
- Migraine disorder
- Pharyngitis
In development for (91)
- Acute lymphoblastic leukemia Phase 2
- Acute myeloid leukemia Phase 2
- Anxiety Phase 2
- Autoimmune thrombocytopenic purpura Phase 1
- B-cell chronic lymphocytic leukemia Phase 1
- Bacterial meningitis Phase 3
- Bone fracture Phase 2
- Borderline personality disorder Phase 2
- Brain injury Phase 2
- Breast cancer Phase 2
- Cancer Phase 3
- Cardiac rhythm disease Phase 1
- Chronic myeloid leukemia Phase 1
- Cleft palate Phase 2
- COVID-19 Phase 3
- Crohn disease Phase 1
- Cutaneous melanoma Phase 2
- Delirium Phase 3
- Diabetes mellitus Phase 1
- Diabetic neuropathy Phase 3
Other linked conditions (12)
- Acute myocardial infarction
- Alzheimer disease
- Asthma
- Chronic rhinosinusitis
- Congenital heart disease
- Drug dependence
- Metastatic malignant neoplasm
- Pain agnosia
- Patellofemoral pain syndrome
- Pyloric stenosis
- Rheumatic disorder
- Seasonal allergic rhinitis